Document:

Biolender Purchase Agreement

 Exhibit 10.139 
 Biolender Purchase Agreement 
 This Purchase Agreement (this “Agreement”) is dated as of
October 31, 2006, is made by and between Biovest International, Inc., a Delaware corporation (“Biovest”) and Accentia Biopharmaceuticals, Inc. a Florida Corporation (“Accentia”). 
 WHEREAS, Biovest and Accentia are the only two members of Biolender LLC, a Delaware Limited Liability Company (“Biolender”); and

 WHEREAS, Biovest wishes to acquire and Accentia wishes to assign all of Accentia’s interest in Biolender subject to the terms
and provisions hereof. 
 NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and
valuable consideration the receipt and adequacy of which are hereby acknowledged, Biovest and Accentia agree as follows: 
 ARTICLE 1

 Purchase and Sale 
 Section 1.1. Transaction. Subject to the terms and conditions of this Agreement, on the Closing Date, Biovest shall purchase and Accentia shall sell and assign to Biovest all of Accentia’s membership interests in Biolender
which shall on the Closing date equal seventy and one half percent (70.5%) of the outstanding ownership interests of Biolender (the “Membership Interests”). 
 Section 1.2 Purchase Price. As the full and complete purchase price for the Membership Interests, Biovest shall issue and deliver to Accentia
Ten million (10,000,000) shares of fully paid and non-assessable common stock of Biovest, $0.01 par value per share (the “Purchase Price”). 
 Section 1.3 Closing. The purchase and sale shall be closed on October 31, 2006 at the offices of Biovest or such other place as the parties may mutually agree (the “Closing”). 

 Section 1.4 Closing Deliveries. 
  

	 	(a)	At the Closing, Accentia shall deliver or cause to be delivered to Biovest the following (the “Accentia Deliverables”): 

  

	 	(i)	A certificate evidencing seventy and one half percent (70.5%) of the outstanding membership interests of Biolender together with a fully executed assignment to Biovest;

  

	 	(ii)	An amendment to the Biolender Limited Liability Company Agreement executed by Accentia reflecting the assignment of Accentia’s membership interests to Biovest and the
withdrawal of Accentia as a member of Biolender; and 

  

	 	(iii)	A waiver executed by Laurus Master Fund, Ltd. of Section 5(a) of that certain Accentia Pledge Agreement, among Accentia, Biovest and Laurus Master Fund, Ltd.

  

	 	(b)	At the Closing, Biovest shall deliver or cause to be delivered to Accentia the following (the “Biovest Deliverables”, together with the Accentia Deliverables, the
“Closing Deliverables”): 

  

	 	(i)	A dully issued and executed certificate evidencing Ten Million shares of fully paid and non-assessable Biovest common stock, $0.01 par value per share, issued in the name of
Accentia; and 

  

	 	(ii)	An amendment to the Biolender Limited Liability Company Agreement by Biovest reflecting the assignment of Accentia’s membership interests to Biovest and the withdrawal of
Accentia as a member of Biolender. 

 ARTICLE 2 
 Representations and Warranties 
 Section 2.1. Representations and
Warranties of Both Parties. Each Party represents and warrants to the other Party that: (i) it is free to enter into this Agreement; (ii) in so doing, it will not violate any other agreement to which it is a party or has received a
waiver of any such violation; and (iii) it has taken all corporate action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement. 
 Section 2.2. Representations and Warranties of Accentia. Accentia hereby represents and warrants to Biovest as follows: 
  

	 	(a)	 Organization; Authority. Accentia is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization
with the requisite corporate power and authority to enter into 

  

 - 2 - 

	 	 
and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution, delivery and
performance by Accentia of the transactions contemplated by this Agreement has been duly authorized by all necessary corporate action on the part of Accentia. This Agreement has been duly executed by Accentia, and when delivered by Accentia in
accordance with terms hereof, will constitute the valid and legally binding obligation of Accentia, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application. Neither the execution and delivery by
Accentia of this Agreement nor the performance of any of the duties and obligations of Accentia under this Agreement constitutes a violation of (a) the certificate of formation or the operating agreement of Accentia; (b) any material
agreement by which Accentia is bound or to which any of its property or assets is subject, or (c) any applicable law. 

  

	 	(b)	Investment Intent. Accentia is acquiring the Securities as principal for its own account for investment purposes only and not with a view to or for distributing or reselling
such Securities or any part thereof, without prejudice, however, to such Accentia’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws. Subject
to the immediately preceding sentence, nothing contained herein shall be deemed a representation or warranty by Accentia to hold the Securities for any period of time. Accentia is acquiring the Securities hereunder in the ordinary course of its
business. 

  

	 	(c)	Access to Information. Accentia acknowledges that it has such knowledge and experience in financial and business matters so as to be capable of evaluating and understanding,
and has evaluated and understood, the merits and risks of an investment in Biovest, and it has been given the opportunity to review and that it has reviewed the Disclosure Materials and has been afforded (i) the opportunity to ask such
questions as it has deemed necessary of, and to receive answers from, representatives of biovest concerning the terms and 

  

	 	(d)	conditions of the offering of the Shares and the merits and risks of investing in the Securities; (ii) access to information about Biovest and its respective financial
condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that Biovest possesses or can acquire without
unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. 

  

 - 3 - 

 Section 2.3. Representations and Warranties of Biovest. Biovest hereby represents and
warrants to Accentia as follows: 
  

	 	(a)	Organization; Authority. Biovest is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite
corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution, delivery and performance by Biovest of the transactions contemplated
by this Agreement has been duly authorized by all necessary corporate action on the part of Biovest. This Agreement has been duly executed by Biovest, and when delivered by Biovest in accordance with terms hereof, will constitute the valid and
legally binding obligation of Biovest, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or
affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application. Neither the execution and delivery by Biovest of this Agreement nor the performance of any of the duties and
obligations of Biovest under this Agreement constitutes a violation of (a) the certificate of formation or the operating agreement of Biovest; (b) any material agreement by which Biovest is bound or to which any of its property or assets
is subject, or (c) any applicable law. 

  

	 	(b)	Authority to Issue Shares. Biovest is duly authorized to issue the shares of Biovest common stock in payment of the Purchase Price; such shares of Biovest common stock shall
be duly issued, outstanding, fully paid and non-assessable upon the delivery at Closing. 

 ARTICLE 3 
 Indemnification 
 Section 3.1 Indemnification of Accentia. Biovest hereby indemnifies and agrees to defend and hold Accentia and its directors, officers, shareholders, partners, employees and agents (each, an “Accentia Indemnified
Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of
investigation (collectively, “Losses”) that any such Accentia Indemnified Party may suffer or incur as a result of: (a) the activities or business conducted by Biovest as manager of Biolender or (b) any misrepresentation, breach
or inaccuracy of any representation, warranty, covenant or agreement made by Biovest herein. 
  

 - 4 - 

 Section 3.2 Indemnification of Biovest. Accentia hereby indemnifies and agrees to defend and
hold Biovest and its directors, officers, shareholders, partners, employees and agents (each, an “Biovest Indemnified Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses,
including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation (collectively, “Losses”) that any such Biovest Indemnified Party may suffer or incur as a result of:
(a) the activities or business conducted by Accentia as a member of Biolender and (b) any misrepresentation, breach or inaccuracy of any representation, warranty, covenant or agreement made by Accentia herein. 
 Section 3.3 Notice of Claims. Promptly after receipt by a Person seeking indemnification pursuant to Section 3.1 or 3.2 (an
“Indemnified Party”) of written notice of any investigation, claim, proceeding or other action in respect of which indemnification is being sought (each, a “Claim”), the Indemnified Party promptly shall notify the Person against
whom indemnification pursuant to Sections 3.1 and/or 3.2 is being sought (the “Indemnifying Party”) of the commencement thereof; but the omission to so notify the Indemnifying Party shall not relieve it from any liability that it otherwise
may have to the Indemnified Party, except to the extent that the Indemnifying Party is materially prejudiced and forfeits substantive rights and defenses by reason of such failure. In connection with any Claim as to which both the Indemnifying Party
and the Indemnified Party are parties, the Indemnifying Party shall be entitled to assume the defense thereof. Notwithstanding the assumption of the defense of any Claim by the Indemnifying Party, the Indemnified Party shall have the right to employ
separate legal counsel and to participate in the defense of such Claim, and the Indemnifying Party shall bear the reasonable fees, out-of-pocket costs and expenses of such separate legal counsel to the Indemnified Party if (and only if):
(i) the Indemnifying Party shall have agreed to pay such fees, costs and expenses, (ii) the Indemnified Party shall reasonably have concluded that representation of the Indemnified Party by the Indemnifying Party by the same legal counsel
would not be appropriate due to actual or, as reasonably determined by legal counsel to the Indemnified Party, potentially differing interests between such parties in the conduct of the defense of such Claim, or if there may be legal defenses
available to the Indemnified Party that are in addition to or disparate from those available to the Indemnifying Party, or (iii) the Indemnifying Party shall have failed to employ legal counsel reasonably satisfactory to the Indemnified Party
within a reasonable period of time after notice of the commencement of such Claim. If the Indemnified Party employs separate legal counsel in circumstances other than as described in the preceding sentence, the fees, costs and expenses of such legal
counsel shall be borne exclusively by the Indemnified Party. Except as provided above, the Indemnifying Party shall not, in connection with any Claim in the same jurisdiction, be liable for the fees and expenses of more than one firm of counsel for
the Indemnified Party (together with appropriate local counsel). The Indemnified Party shall not, without the prior written consent of the Indemnifying Party (which consent shall not unreasonably be withheld), settle or compromise any Claim or
consent to the entry of any judgment that does not include an unconditional release of the Indemnifying Party from all liabilities with respect to such Claim or judgment or contain any admission of wrongdoing. 
  

 - 5 - 

 ARTICLE 4 
 Miscellaneous 
 Section 4.1. Fees and Expenses. Except as set forth in Article 3
hereof, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of the
Transaction Documents. The Company shall pay all stamp and other taxes and duties levied in connection with the sale of the Shares. 
 Section 4.2. Entire Agreement. This Agreement together with the Exhibits and Closing Deliverables, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements,
understandings, discussions and representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents and exhibits. 
 Section 4.3. Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile (provided the sender receives a machine-generated confirmation of successful
transmission) at the facsimile number specified in this Section prior to 6:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in this Section on a day that is not a Trading Day or later than 6:30 p.m. (New York City time) on any Trading Day, (c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows: 
  

					
	If to Biovest:    	  	Biovest International, Inc.
		  	Attn.: Chief Executive Officer
		  	Biotech Building 4
		  	377 Plantation Street
		  	Worcester, MA 01605
		  	Telephone:	  	(508) 793-0001
		  	Facsimile:	  	(508) 798-0899

  

 - 6 - 

					
	With a copy to:    	  	Nixon Peabody LLP
		  	Attn.: Herbert F. Stevens
		  	Suite 900
		  	401 9th Street, NW
		  	Washington, DC 20004
		  	Telephone:	  	(202) 585-8811
		  	Facsimile:	  	(202) 585-8080
		
	If to Accentia:	  	Accentia Biopharmaceuticals, Inc.
		  	Attn.: Chief Executive Officer
		  	Suite 350
		  	324 South Hyde Park Ave.
		  	Tampa, FL, 33606
		  	Telephone:	  	(813) 864-2554
		  	Facsimile:	  	(813) 258-6912
		
	With a copy to:	  	Foley Lardner LLP
		  	Attn.: Curt Creely
		  	Suite 2700
		  	100 North Tampa St.
		  	Tampa, FL 33601-3391
		  	Telephone:	  	(813) 229-2300
		  	Facsimile:	  	(813) 221-4210
		
		  	or such other address as may be designated in writing hereafter, in the same manner, by such person.

 Section 4.4. Amendments; Waivers; No Additional Consideration. No provision of this
Agreement may be waived or amended except in a written instrument signed by Biovest and Accentia. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the
future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 Section 4.5. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their
successors and permitted assigns. Either party may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party. 
 Section 4.6. No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any
provision hereof be enforced by, any other Person, except as otherwise set forth in Sections 3.1 and 3.2 (with respect to rights to indemnification). 
  

 - 7 - 

 Section 4.7. Governing Law. All questions concerning the construction, validity, enforcement
and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof. 
 Section 4.8. Survival. The representations, warranties, agreements and covenants contained herein shall survive the Closing and the delivery
of the Closing Deliverables. 
 Section 4.9. Execution. This Agreement may be executed in two or more counterparts, all of which
when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same
counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as
if such facsimile signature page were an original thereof. 
 Section 4.10. Severability. If any provision of this Agreement is
held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and
enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. 
 Section 4.11. Waiver of Potential Conflicts of Interest. Biovest and Accentia hereby acknowledge that Accentia owns more than a majority of the outstanding capital stock of Biovest, and that certain
directors, officers and employees of Biovest also have positions as officers, directors or employees of Accentia. In light of the potential conflicts of interest resulting from the interrelationship of the parties, Biovest has committed to submit
this Agreement and the potential conflicts of interest arising there from to the Biovest Audit Committee. All members of the Biovest Audit Committee are independent from any relationship with Accentia. Further, Biovest has committed that the Biovest
Audit Committee shall engage independent legal counsel and Accentia has also committed that it shall engage independent legal counsel because the general counsel and entire legal staff used by both Biovest and Accentia are shared resources by
Biovest and Accentia. The role of general counsel and in-house legal staff of Biovest and Accentia shall be limited to initial drafting and to supporting independent legal counsel. Biovest further represents that this Agreement shall not be
submitted to the full Board of Directors of Biovest unless this Agreement has been recommended by the Biovest Audit Committee. Biovest, following the recommendation of its Audit Committee and with the approval of its Board of Directors, by executing
this Agreement shall be deemed to expressly acknowledge and waive the potential conflicts of interest associated with this Agreement. Only after receipt of the commitments, representations and mutual assurances that all reasonable and necessary
steps to assure that all potential conflicts of interest have been fully disclosed, addressed, and fairly and completely resolved or waived by Biovest and Accentia, have the parties entered into this Agreement. 
  

 - 8 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized signatories as of the date first indicated above. 
  

			
	 BIOVEST INTERNATIONAL, INC.

		
	By:	 	/s/ Steven Arikian
		 	Steven Arikian, M.D.
		 	President and Chief Executive Officer

  

			
	 ACCENTIA BIOPHARMACEUTICALS, INC.

		
	By:	 	/s/ Francis E. O’Donnell, Jr.
		 	Frank O’Donnell, M.D.
		 	President and Chief Executive Officer

  

 - 9 -Consent, the Company, Biolender, AutovaxID and Laurus

 EXHIBIT 10.140 
 CONSENT 
 This Consent (the “Consent”), dated as of October 31, 2006, is
entered into by and among Accentia Biopharmaceuticals, Inc., a Florida corporation (“Accentia”), Analytica International, Inc. (formerly The Analytica Group, Inc.), a Florida corporation (“Analytica”), Biolender,
LLC, a Delaware limited liability company (“Biolender”), TEAMM Pharmaceuticals, Inc., a Florida corporation (“TEAMM” and together with Accentia, Analytica, TEAMM and Biolender, the “Accentia Credit
Parties” and each, an “Accentia Credit Party”), and Laurus Master Fund, Ltd., a Cayman Islands company (“Laurus”), in connection with (i) that certain Note and Warrant Purchase Agreement (as amended,
modified or supplemented from time to time, the “Purchase Agreement” and, together with the Related Agreements and Security Documents, each as defined therein, the “Biovest Funding Documents”), dated as of
March 31, 2006, by and between Biovest International, Inc., a Delaware corporation (“Biovest”, together with the Accentia Credit Parties, the “Credit Parties” and each, a “Credit Party”),
certain Subsidiaries of Biovest and Laurus, (ii) that certain Securities Purchase Agreement, dated as of April 29, 2005, by and between Accentia and Laurus (as amended, modified or supplemented from time to time, the “Accentia
Purchase Agreement” and, together with the Related Agreements referred to therein, the “Accentia Purchase Documents”) and (iii) that certain Security Agreement, dated as of April 29, 2005, and amended and restated
as of February 13, 2006, by and between Accentia, Analytica, TEAMM and Laurus (as amended, modified or supplemented from time to time, the “Accentia Security Agreement” and, together with the Ancillary Agreements referred to
therein, the “Accentia Security Documents” and together with the Accentia Purchase Documents, the “Accentia Funding Documents” and, together with the Biovest Funding Documents, the “Laurus Funding
Documents”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Laurus Funding Documents, as applicable. 
 WHEREAS, the Credit Parties wish to obtain Laurus’ consent to the following proposed business transactions and agreements: (i) the sale by Accentia of certain or all of its rights in the Xodol product line;
(ii) the sale by Accentia of its rights in the Histex product line; (iii) the sale by Accentia of the clinical trial division of IMOR-Analytica GmbH, a corporation organized under the laws of Germany and wholly-owned subsidiary of
Analytica (“IMOR”); (iv) the sale by Accentia to Biovest of Accentia’s ownership interest in Biolender LLC, (v) an increase of up to $3.1 million dollars in aggregate principal amount of inter-company loans from
Accentia to Biovest; (vi) certain modifications to Accentia’s business plan relating specifically to the reduction in the amount of Accentia’s voting equity ownership percentage of Biovest, the realingment of the focus and business
emphasis of Accentia’s specialty pharmaceuticals sales division on oncology products and pain products and the role to be maintained by Accentia in the commercializing Biovest’s biologic products; (vii) termination of the Biologic
Products Commercialization Agreement, dated as August 17, 2004 between Accentia and Biovest (as amended, modified or supplemented from time to time, the “Commercialization Agreement”) and the grant by Biovest to Accentia of a
passive 19.5% royalty to be paid by Biovest to Accentia on the sale of biologic products (“Royalty Grant”); and (viii) termination of the anti-dilution/first right of refusal right Agreement between Accentia and Biovest, dated
as of June 16, 2003 (the “Right of Refusal Agreement”) (collectively the “Proposed Transactions”); 
  

 WHEREAS, each Credit Party acknowledges that the Proposed Transactions require Laurus’s consent
under the Laurus Funding Documents; 
 WHEREAS, Laurus has agreed to consent to the Proposed Transaction on the terms and conditions set
forth herein; 
 WHEREAS, Accentia has agreed to issue, grant and deliver to Laurus the Additional Warrant (as defined below). 
 NOW, THEREFORE, in consideration of the above, and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree as follows: 
 1. Laurus hereby consents to: 
  

	 	a.	the proposed sale by Accentia of certain or all of its rights in the Xodol product line in an arm’s-length transaction negotiated in good faith by the parties (the
“Xodol Sale”), the sale by Accentia of its rights in the Histex product line in an arm’s-length transaction negotiated in good faith by the parties (the “Histex Sale”); and the sale by Accentia of the clinical
trial division of IMOR in an arm’s-length transaction negotiated in good faith by the parties (the “IMOR Sale” and together with the Xodol Sale and the Histex Sale, the “Accentia Sales” and each, an
“Accentia Sale”), provided that, on each date on or after the Consent Effective Date upon which Accentia or any of its Subsidiaries receives Net Sale Proceeds (as defined below) from any Accentia Sale, an amount equal to fifty
percent (50%) of the Net Sale Proceeds (notwithstanding that certain of such assets may constitute TEAMM Transactions as defined in the Overadvance Side Letter, dated as of July     , 2006) as a mandatory repayment of
outstanding Obligations under the Accentia Funding Documents in the following manner (i) accrued and unpaid interest and fees (including any applicable prepayment fees) and (ii) outstanding principal. “Net Sale Proceeds”
shall mean for any sale of assets, the gross cash proceeds (including any cash received by way of deferred payment pursuant to a promissory note, receivable or otherwise, but only as and when received) received from any sale of assets, net of
(i) reasonable transaction costs (including, without limitation, any underwriting, brokerage or other customary selling commissions and reasonable legal, advisory and other fees and expenses, including consent, title, filing and recording
expenses, associated therewith) and payments of unassumed liabilities relating to the assets sold at the time of, or within 30 days after, the date of such sale, (ii) the amount of such gross cash proceeds required to be used to repay any
indebtedness or other outstanding obligation (other than indebtedness of Laurus pursuant to the Laurus Funding Documents) related to such sale (if any), and (iii) the estimated marginal increase in income taxes which will be payable by
Accentia’s consolidated group with respect to the fiscal year in which the sale occurs as a result of such sale; 

  

 2 

	 	b.	the sale by Accentia to Biovest of all of Accentia’s equity ownership interest in Biolender, LLC in exchange for the issuance by Biovest to Accentia of no less than 10,000,000
shares of its common stock, par value $0.01; 

  

	 	c.	(I) an increase by up to $3.1 million dollars (the “$3.1M Increase”) of the inter-company loan (the “Accentia Inter-Company Loan”) extended by
Accentia to Biovest and (II) to release to Biovest as part of NMTC Financing Tranche 2 all amounts remaining in the Restricted Account (as defined in the Purchase Agreement); provided that, (i) the $3.1M Increase shall be used by Biovest in
connection with Tranche #2 of Biovest’s NMTC financing as evidenced by NMTC Finanicng closing documents dated no later than November 15, 2006, by and among AutovaxidID, Inc., a Florida corporation (“AutovaxID”), Biolender,
LLC and Biovest (the “NMTC Financing Tranche 2”), (ii) after giving effect to the $3.1M Increase, the Accentia Inter-Company Loan shall be in principal amount of no more than $9.6 million (iii) the NMTC Financing Tranche 2
shall close on or prior to November 15, 2006, (iv) Biovest shall receive cash proceeds from the NMTC Financing Tranche 2 of no less than $5,500,000, (v) Biovest shall use no more than $1.1 million from the cash proceeds of the NMTC
Financing Tranche 2 to repay the Accentia Inter-Company Loan, (vi) the NMTC Financing Tranche 2 and the Accentia Inter-Company Loan shall be subordinated in right of payment and priority to the Obligations as defined in the Laurus Funding
Documents in form and substance reasonably satisfactory to Laurus, and (vii) the documentation evidencing such NMTC Financing Tranche 2, $3.1M Increase and Accentia Inter-Company Loan shall be in form and substance satisfactory to Laurus and
shall in no way adversely impact Laurus’ rights and remedies under the Laurus Funding Documents; 

  

	 	d.	the termination by Accentia and Biovest of the Commercialization Agreement between Accentia and Biovest as part of the establishment of a passive 19.5% royalty entitlement; provided
that, Accentia receives simultaneous with such termination as consideration therefore a minimum of five million (5,000,000) duly authorized and issued shares of Biovest common stock, par value $0.01 and the Royalty Grant; provided further that,
the documentation pertaining to the aforesaid is in form and substance satisfactory to Laurus and shall in no way adversely impact Laurus’ rights and remedies under the Accentia Funding Documents; and 

  

	 	e.	the termination of Accentia’s anti-dilution/first right of refusal Agreement with Biovest provided that Accentia receives as consideration therefor a minimum of five million
(5,000,000) duly authorized and issued shares of Biovest common stock, par value $0.01. 

 2. Laurus hereby waives its
Financing Right of First Refusal contained in the Purchase Agreement with respect to the NMTC Financing Tranche 2. 
  

 3 

 3. Accentia hereby issues a seven year warrant (the “Additional Warrant”) to Laurus to
purchase 10,000,000 shares of outstanding common stock of Biovest owned by Accentia with an exercise price of $0.01 per share acquired thereunder, such Additional Warrant to be in the form attached hereto as Exhibit A. In connection with the
issuance by Accentia of the Additional Warrant, subject to the terms and conditions of the Additional Warrant, Accentia hereby agrees to cause the Biovest transfer agent (the “Transfer Agent”) to issue and deliver to Laurus (or its
designee), upon receipt of an exercise notice in respect of the Additional Warrant and the original Biovest stock certificate pledged by Accentia to Laurus representing not less than the number of Biovest shares being exercised in the exercise
notice and otherwise held by Laurus as collateral and an appropriate stock power executed by Accentia, (i) a duly executed stock certificate issued in the name of “Laurus Master Fund, Ltd.” for such number of shares of Biovest common
stock set forth in the applicable exercise notice (to the extent that the aggregate of all such exercise notices issued under the Additional Warrant are not in excess of 10,000,000 shares (subject to adjustments as set forth in the Additional
Warrant)) which shares shall have the appropriate SEC restrictive legend unless Transfer Agent receives an opinion from Accentia’s counsel that such legend is not required and (ii) a duly executed replacement stock certificate standing in
the name of Accentia evidencing the shares of Biovest common stock remaining under the stock certificate exchanged by Laurus and not otherwise transferred in the name of Laurus Master Fund, Ltd; provided, that Biovest will cause the Transfer Agent
to acknowledge in writing its agreement with the foregoing and that no additional approval shall be required of Accentia and/or Biovest to effect the foregoing issuances (the “Transfer Agent Acknowledgement”). 
 4. Each consent set forth herein shall be effective as of the first date (the “Consent Effective Date”) when (i) each Credit Party
shall have executed and delivered to Laurus (or its designee) its respective counterpart to this Consent; (ii) Accentia shall have delivered to Laurus (or its designee) a duly executed and witnessed Additional Warrant in the form attached
hereto as Exhibit A; (iii) Accentia shall have agreed to deliver to Laurus (or its designee) within five business days following closing of the transactions described in Section 1(b), (d) and (e) above, the original stock
certificates evidencing all equity interests held by Accentia in Biovest (to the extent not already delivered), together with duly executed undated stock powers executed in blank, as well as a duly executed Transfer Agent Acknowledgement;
(iv) AutovaxID shall have agreed that upon Closing of the NMTC Financing Tranche 2 it will deliver to Laurus (or its designee) a Joinder Agreement in the form attached hereto as Exhibit B; and (v) each of AutovaxID, Biovest,
Accentia and St. Louis New Markets Tax Credit Fund-II, LLC shall have agreed that upon Closing of the NMTC Financing Tranche 2 it will deliver to Laurus (or its designee) a Subordination Agreement in form attached hereto as Exhibit C or in
form and substance approved by Laurus and the parties thereto (the “St. Louis NMTC Subordination Agreement”). 
 5. Accentia and
Biovest hereby agree to deliver to Laurus (or its designee) each document evidencing the Proposed Transactions and the NMTC Financing Tranche 2, including without limitation, the St. Louis NMTC Subordination Agreement, each duly executed and
delivered by the respective parties thereto. 
  

 4 

 6. Except as specifically set forth in this Consent, there are no amendments, modifications or waivers to
the Laurus Funding Documents, and all of the forms, terms and provisions of the Laurus Funding Documents remain in full force and effect. 
 7. On the date hereof, after giving effect to this Consent, each Credit Party hereby represents and warrants to Laurus, as applicable, that (i) no Event of Default exists under the Laurus Funding Documents, (ii) all
representations, warranties and covenants made by the Credit Parties in connection with the Laurus Funding Documents are true, correct and complete and (iii) all of the Credit Parties’ covenant requirements have been met. 
 8. Each of Accentia and Biovest agree to file with the SEC, to the extent required by applicable law and/or regulation, public disclosure of this Consent
and the matters address herein in the appropriate form required by the SEC for such filing within four (4) days of the date hereof. 
 9. This Consent shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure to the benefit of and be enforceable by each of the parties hereto and their respective successors and permitted
assigns. THIS CONSENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK This Consent may be executed in one or more counterparts, each of which shall be deemed an original but all of
which shall constitute one instrument. Execution of this Consent and delivery of a signature page by facsimile or email shall bind and constitute valid delivery of this Consent by the sending executing party to be followed by originals signed by the
executing party. 
 [Balance of Page Left Intentionally Blank] 
  

 5 

 IN WITNESS WHEREOF, each Credit Party and Laurus have caused their duly authorized representatives
to duly execute this Consent on the date as first written above. 
  

			
	LAURUS MASTER FUND, LTD.
		
	By:	 	/s/ Eugene Grin
	Name:	 	Eugene Grin
	Title:	 	Director
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	/s/ Francis E. O’Donnell, Jr.
		 	Name: Francis E. O’Donnell, Jr.
		 	Title: CEO
	
	 BIOLENDER, LLC
 By Biovest
International, Inc., its managing member

		
	By:	 	/s/ Steven Arikian
		 	Name: Steven Arikian
		 	Title: Chairman & CEO
	
	ANALYTICA INTERNATIONAL, INC.
		
	By:	 	/s/ Steven Arikian
		 	Name: Steven Arikian
		 	Title: Chairman & CEO
	
	TEAMM PHARMACEUTICALS, INC.
		
	By:	 	/s/ Francis E. O’Donnell, Jr.
		 	Name: Francis E. O’Donnell, Jr.
		 	Title: CEO

  

 EXHIBIT A 
 WARRANT 
  

 7 

 EXHIBIT B 
 AUTOVAXID, INC. TO BIOVEST FUNDING DOCUMENTS JOINDER 
  

 8 

 EXHIBIT C 
 NEW MARKET TAX CREDIT FUND II, LLC SUBORIDNATION AGREEMENT 
  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]